The present invention relates generally to systems and method for preventing contamination of access ports. In particular, this disclosure discusses an antimicrobial access cap which is configured to receiving an access port of an intravascular device, an inner surface of the antimicrobial access cap having been treated with an antimicrobial agent.
In the fields of medicine and health care, a patient's skin may be punctured in a variety of manners and for a variety of reasons. In one example, a cannula or an intravenous (“IV”) catheter is forced through the patient's skin into an interior space, such as the patient's vasculature. In this example, the cannula or IV catheter can be used for infusing fluid (e.g., saline solution, medicaments, and/or total parenteral nutrition) into the patient, withdrawing fluids (e.g., blood) from the patient, and/or monitoring various parameters of the patient's vascular system. The cannula or IV catheter generally comprises a distal end which is positioned within the patient's vasculature, and a proximal end which is located external to the vasculature of the patient. As such, a physician may access the vasculature of the patient via the exposed, proximal end of the IV catheter.
While an IV catheter is convenient for providing prolonged access to the vasculature of the patient, the exposed portions of the catheter are susceptible to contamination by various strains of bacteria and viruses. Indeed, it is estimated that each year hundreds of thousands of patients in the United States alone develop some form of bloodstream infection that is caused by pathogens that were communicated to the patient through or because of an IV catheter or another IV access device, such as a hypodermic needle. Many of the bacterial pathogens that cause these catheter-related bloodstream infections are introduced into the vasculature of the patient through repeated attempts to access the patient's vasculature via the exposed portion of the IV catheter. Bacterial colonies which develop on the exposed portion of the IV catheter are transferred to the patient by way of a needle or syringe which is inserted into the proximal, exposed portion of the IV catheter.
Often, these catheter-related bloodstream infections cause patient illness and, in some cases, death. Furthermore, because some infections are caused by bacterial strains (e.g., Methicillin-resistant Staphylococcus aureus (“MRSA”) and Vancomycin-resistant Enterococci (“VRE”)) that are resistant to antibiotics, such infections can be hard to treat and may be becoming more prevalent. Additionally, because patients that have a bloodstream infection may require additional medical treatment, catheter-related bloodstream infections may also be associated with increased medical costs.
In an attempt to limit bloodstream infections (i.e., catheter-related infections) in hospital, outpatient, home care, and other health care settings, many have implemented sanitary techniques. For example, many health care providers have placed a strong emphasis on wearing gloves, cleaning hands, and cleaning the exposed portion of the IV catheter before inserting a needle or syringe. Some health care providers have devised a medical device cap which includes a cleaning solution, as taught in U.S. patent application Ser. No. 12/877,519, which is incorporated herein by reference, in its entirety. However, the demands of some medical emergency situations often preclude the use of currently available sanitary techniques.
Thus, while methods and systems currently exist to reduce bloodstream infections, challenges still exist. Accordingly, it would be an improvement in the art to augment or even replace current techniques with other techniques.
The systems and methods of the present disclosure have been developed in response to problems and needs in the art that have not yet been fully resolved by currently available infusion systems and methods. Thus, these systems and methods are developed to provide for safer and more efficient rapid infusion procedures.
In some implementations of the present invention, a device is provided for preventing contamination of an access port, the device including an access cap having an inner surface defining a space for receiving a portion of the access port, the inner surface further including an antimicrobial agent. In some implementations, the access port is a portion of an intravenous or intravascular device, such as a y-port. In other implementations, the access port is a male or female luer of an intravascular device. Further still, in some aspects of the present invention the access port is at least one of a syringe, a catheter, a catheter hub, a needle, a piece of intravenous tubing, and/or an input or output valve of a medical device, such as centrifuge or a dialysis machine.
In some aspects of the invention, an access cap is provided which is configured to cover and thereby protect an exposed portion of the access port, thereby preventing contamination of the access port by bacteria or viruses. In some implementations, an access cap is provided which is connected to a portion of the access port. For example, in some implementations access cap is connected or attached to the access port via a tether. In other implementations, access cap is attached to the access port via a hinged tether. Further, in other implementations the access cap is slidably coupled to the intravascular device. Further still, in some implementations the access cap is pivotally coupled at least one of the access port and the intravascular device.
The antimicrobial agent is generally provided on a surface of the access cap such that when the access cap is placed onto the access port, the antimicrobial agent is in direct contact with an exposed portion of the access port. In some implementations, the antimicrobial agent is applied directly to the access cap. In other embodiments, the antimicrobial agent is applied to a material (such as a sponge, a foam, or a gel) which is applied to a surface of the access cap. Thus, when the access cap is placed adjacent to the access port, the antimicrobial agent maintains contact with an exposed or external portion of the access port.
In some implementation of the present invention, a method for preventing contamination of an access port is provided. Some aspects of the invention provide steps for providing a cap having an inner surface defining a space for receiving a portion of the access port, applying an antimicrobial agent to a portion of the inner surface, and attaching the cap to the access port. In some implementations, the access port is an intravenous or intravascular device. In other implementations, a further step is provided wherein the antimicrobial agent is retained by a material disposed within the inner surface of the cap.
Further still, in some implementations of the present invention an access port adapter, or an intravenous device adapter is provided having a body which includes a proximal end and a distal end, the proximal end having a first coupling surface for receiving a first or upstream intravascular device, and the distal end having a second coupling surface for receiving a second or downstream intravascular device. The access port adapter further includes a cap or access cap coupled to the body of the access port adapter, the cap having an inner surface defining a space for receiving a portion of the access port, and an antimicrobial agent disposed within the inner surface of the cap.
In some aspects of the present invention, the first and second coupling surfaces are threaded. In other aspects of the invention, a material is disposed within the inner surface of the cap which is capable of receiving and storing an antimicrobial agent. The material generally includes adsorptive or absorptive properties which allow the antimicrobial agent to be stored within the material. In some implementations, the material includes at least one of a sponge, a gel, a foam material, a woven material, a non-woven material, and a polymeric material.
The present invention further includes methods for manufacturing an antimicrobial IV access cap, wherein the method includes steps for coupling an access cap to a portion of an intravenous device, the intravenous device having an access port, and inserting an antimicrobial agent within an inner surface of the access cap, the inner surface of the access cap being configured to receive an exposed portion of the access port. The method for manufacturing the antimicrobial IV access cap further includes steps for hingedly coupling the access cap to a body portion of the intravenous device, as well as modifying the tethered connection between the access cap and the intravenous device with various other features, discussed in detail below.
In order that the manner in which the above-recited and other features and advantages of the invention are obtained will be readily understood, a more particular description of the invention briefly described above will be rendered by reference to specific embodiments thereof which are illustrated in the appended drawings. These drawings depict only typical embodiments of the invention and are not therefore to be considered to limit the scope of the invention.
Embodiments of the present invention will be best understood by reference to the drawings, wherein like reference numbers indicate identical or functionally similar elements. It will be readily understood that the components of the present invention, as generally described and illustrated in the figures herein, could be arranged and designed in a wide variety of different configurations. Thus, the following more detailed description, as represented in the figures, is not intended to limit the scope of the invention as claimed, but is merely representative of presently preferred embodiments of the invention.
The systems and methods of the present invention are generally designed for use in combination with a vascular infusion system capable delivering an infusant to the vascular system of a patient. Referring now to
Referring now to
Cap 10 generally comprises an inner surface 14 which defines a space for receiving a portion 16 of access port 20. The inner surface 14 further defines a space for storing an antimicrobial agent 40. In some embodiments, antimicrobial agent 40 comprises a material, solution, compound or coating which prevents colonization of undesirable bacteria and viruses. In some embodiments, antimicrobial agent 40 is selected from the group of chlorhexidine gluconate, chlorhexidine acetate, PCMX, Triclosan, silver sulfadiazine, and the like. In other embodiments, antimicrobial agent 40 comprises a topical antibiotic, such as Mupirocin, bacitracine, and the like.
In some embodiments, antimicrobial agent 40 is applied directly to the inner surface 14 of access cap 10. In other embodiments, antimicrobial agent 40 is retained within the inner surface 14 of access cap 10 via a material, such as a sponge material, a gel material, a foam material, a woven material, a non-woven material, and/or a polymeric material. The antimicrobial agent 40 is applied to the inner surface 14 of cap 10 such that when cap 10 is placed over access port 20, antimicrobial agent 40 contacts an opening surface 32 of access port 20. In this way, antimicrobial agent 40 prevents colonization of bacterial and/or viruses within access port 20.
Referring now to
Distal end 54 is threadedly coupled to downstream intravenous device 60 via the second threaded surface 64 thereby preventing bacterial colonization between adapter 50 and downstream intravenous device 60, as shown in
One having skill in the art will appreciate that the interaction between access cap 10 and intravenous device adapter 50 may be accomplished by any number of different techniques. For example, in some embodiments access cap 10 is tethered to the outer surface 56 of adapter 50, as shown in
With reference to
In some embodiments, tether 80 comprises a loop 82 configured to ride within a channel 56 formed on an outer surface of adapter 50, as shown in
In some embodiments, tether 80 further comprises a lever 84 whereby the user by shift tether 80 in a proximal direction 86 with one hand, thereby advancing access cap 10 in a proximal direction which results in access cap 10 being removed from proximal end 52, as shown in
In some embodiments, intravenous device adapter 50 further comprises a hinged antimicrobial cap 100, as shown in
In some embodiments, access cap 100 is hingedly coupled to adapter 50 via a hinged tether 120. Hinged tether 120 includes a hinged joint 122 which moves access cap 100 between a closed position (as shown in
Referring now to
In some embodiments, tether 150 comprises a loop 152 which defines a middle portion of tether 150, as shown in
Referring now to
The pivoting connection 172 between tether 170 and adapter 50 enables tether 170 to be pivoted or rotated between a closed position (as shown in
A user accesses proximal end 52 of adapter 50 by pushing pad 174 in rearward direction 182, thereby causing access cap 100 to be displaced from proximal end 52, as shown in
In some embodiments, a section of intravenous tubing 240 comprises a male luer connector 250. The male luer connector 250 enables access to the intravenous tubing 240. For example, in some embodiments an infusion device, such as a syringe (not shown), is attached to the intravenous tubing 240 via a threaded connection between the male luer connector 250 and the syringe. In some embodiments, an exposed surface of male luer connector 250 is protected with a spring hinge cap 260, as shown in
In other embodiments, spring hinge cap 260 is fitted over male luer connector 250 such that the proximal threaded surface of male luer connector 250 passes through a body portion of cap 260 and is positioned inside cap 260. As such, male luer connector 250 may still be accessed by manipulating cap 260 to reveal the proximal threaded surface of male luer connector 250.
In some embodiments, spring hinge cap 260 comprises a first tab 264 and a second tab 266, each of which is hingedly coupled to a body portion of spring hinge cap 260. In some embodiments, first and second tabs 264 and 266 are further pivotally coupled to a body portion of cap 260 thereby enabling an opened position, as shown in
In some embodiments, tabs 264 and 266 further comprise an inner surface 268 and 270, respectively, which form a seal when in the closed position. In some embodiments, inner surfaces 268 and 270 are coated with an antimicrobial agent, in accordance with the teachings of the present invention. Thus, when in the closed position the exposed proximal surfaces of male luer connector 250, or proximal threads 262 of cap 260, are contained within the antimicrobial agent coating of tabs 264 and 266, thereby preventing undesirable contamination thereof.
Referring now to
Lid 282 comprises an inner surface 284 which forms a closed end of the internal space when lid 282 is in a closed position, as shown in
In some embodiments, lid 282 further comprises a lever 294. Lever 294 comprises a first end 286 hingedly coupled to body portion 290, and a second end rigidly coupled to lid 282. Lever 294 further comprises a joint 300 whereby lid 284 and second end 288 pivot into an opened position when lever 294 pressed inwardly towards body portion 290, as shown in
The present invention may be embodied in other specific forms without departing from its structures, methods, or other essential characteristics as broadly described herein and claimed hereinafter. The described embodiments are to be considered in all respects only as illustrative, and not restrictive. The scope of the invention is, therefore, indicated by the appended claims, rather than by the foregoing description. All changes that come within the meaning and range of equivalency of the claims are to be embraced within their scope.
This application claims priority to U.S. Provisional Patent Application No. 61/364,447, entitled ANTIMICROBIAL I.V. ACCESS CAP, filed on Jul. 15, 2010, which is incorporated herein in its entirety.
Number | Name | Date | Kind |
---|---|---|---|
2961682 | Wurmbock et al. | Nov 1960 | A |
4280632 | Yuhara | Jul 1981 | A |
4282891 | Duceppe | Aug 1981 | A |
4354490 | Rogers | Oct 1982 | A |
4417890 | Dennehey et al. | Nov 1983 | A |
4432764 | Lopez | Feb 1984 | A |
4440207 | Genatempo et al. | Apr 1984 | A |
4444310 | Odell | Apr 1984 | A |
4584192 | Dell et al. | Apr 1986 | A |
4624664 | Peluso et al. | Nov 1986 | A |
4626664 | Grise | Dec 1986 | A |
4655762 | Rogers | Apr 1987 | A |
4671306 | Spector | Jun 1987 | A |
4716032 | Westfall et al. | Dec 1987 | A |
4753358 | Virca | Jun 1988 | A |
4778447 | Velde et al. | Oct 1988 | A |
4915934 | Tomlinson | Apr 1990 | A |
4925668 | Khan et al. | May 1990 | A |
4989733 | Patry | Feb 1991 | A |
4991629 | Ernesto et al. | Feb 1991 | A |
5023082 | Friedman et al. | Jun 1991 | A |
5195957 | Tollini | Mar 1993 | A |
5242425 | White et al. | Sep 1993 | A |
5334388 | Hoang et al. | Aug 1994 | A |
5335373 | Dresdner et al. | Aug 1994 | A |
5512199 | Khan et al. | Apr 1996 | A |
5547662 | Khan et al. | Aug 1996 | A |
5554106 | Layman-Spillar et al. | Sep 1996 | A |
5554135 | Menyhay | Sep 1996 | A |
5569207 | Gisselberg et al. | Oct 1996 | A |
5616338 | Fox, Jr. et al. | Apr 1997 | A |
5620424 | Abramson | Apr 1997 | A |
5639310 | Giampaolo, Jr. | Jun 1997 | A |
5641464 | Briggs, III et al. | Jun 1997 | A |
5686096 | Khan et al. | Nov 1997 | A |
5694978 | Heilmann et al. | Dec 1997 | A |
5702017 | Goncalves | Dec 1997 | A |
5706944 | Hoang et al. | Jan 1998 | A |
5722537 | Sigler | Mar 1998 | A |
5743884 | Hasson et al. | Apr 1998 | A |
5792120 | Menyhay | Aug 1998 | A |
5817344 | Hoang et al. | Oct 1998 | A |
5861440 | Gohla et al. | Jan 1999 | A |
5954957 | Chin-Loy et al. | Sep 1999 | A |
5989229 | Chiappetta | Nov 1999 | A |
6045539 | Menyhay | Apr 2000 | A |
6051609 | Yu et al. | Apr 2000 | A |
6116468 | Nilson | Sep 2000 | A |
6117114 | Paradis | Sep 2000 | A |
6196998 | Jansen et al. | Mar 2001 | B1 |
6227391 | King | May 2001 | B1 |
6337357 | Fukunishi et al. | Jan 2002 | B1 |
6413539 | Shalaby | Jul 2002 | B1 |
6488942 | Ingemann | Dec 2002 | B1 |
6523686 | Bae | Feb 2003 | B1 |
RE38145 | Lynn | Jun 2003 | E |
6708363 | Larsen | Mar 2004 | B2 |
6846846 | Modak et al. | Jan 2005 | B2 |
6861060 | Luriya et al. | Mar 2005 | B1 |
6911025 | Miyahara | Jun 2005 | B2 |
6994315 | Ryan et al. | Feb 2006 | B2 |
7083605 | Miyahara | Aug 2006 | B2 |
7198611 | Connell et al. | Apr 2007 | B2 |
7198800 | Ko | Apr 2007 | B1 |
7268165 | Greten et al. | Sep 2007 | B2 |
7282186 | Lake, Jr. et al. | Oct 2007 | B2 |
7452349 | Miyahara | Nov 2008 | B2 |
7682561 | Davis et al. | Mar 2010 | B2 |
7704935 | Davis et al. | Apr 2010 | B1 |
7763006 | Tennican | Jul 2010 | B2 |
7828186 | Wales | Nov 2010 | B2 |
7922701 | Buchman | Apr 2011 | B2 |
8065773 | Vaillancourt et al. | Nov 2011 | B2 |
8113731 | Cable, Jr. et al. | Feb 2012 | B2 |
8162899 | Tennican | Apr 2012 | B2 |
8167847 | Anderson et al. | May 2012 | B2 |
8491546 | Hoang et al. | Jul 2013 | B2 |
20010016589 | Modak et al. | Aug 2001 | A1 |
20020144705 | Brattesani et al. | Oct 2002 | A1 |
20030072781 | Pelerin | Apr 2003 | A1 |
20030109853 | Harding et al. | Jun 2003 | A1 |
20030153865 | Connell et al. | Aug 2003 | A1 |
20030162839 | Symington et al. | Aug 2003 | A1 |
20040004019 | Busch | Jan 2004 | A1 |
20040039349 | Modak et al. | Feb 2004 | A1 |
20040258560 | Lake, Jr. et al. | Dec 2004 | A1 |
20050124970 | Kunin et al. | Jun 2005 | A1 |
20050147524 | Bousquet | Jul 2005 | A1 |
20050147525 | Bousquet | Jul 2005 | A1 |
20050222542 | Burkholz et al. | Oct 2005 | A1 |
20060030827 | Raulerson et al. | Feb 2006 | A1 |
20060165751 | Chudzik et al. | Jul 2006 | A1 |
20060239954 | Sancho | Oct 2006 | A1 |
20070112333 | Hoang et al. | May 2007 | A1 |
20070202177 | Hoang | Aug 2007 | A1 |
20070225660 | Lynn | Sep 2007 | A1 |
20070282280 | Tennican | Dec 2007 | A1 |
20080019889 | Rogers et al. | Jan 2008 | A1 |
20080027399 | Harding et al. | Jan 2008 | A1 |
20080033371 | Updegraff et al. | Feb 2008 | A1 |
20080075761 | Modak et al. | Mar 2008 | A1 |
20080095680 | Steffens et al. | Apr 2008 | A1 |
20080147047 | Davis et al. | Jun 2008 | A1 |
20080177250 | Howlett et al. | Jul 2008 | A1 |
20080182921 | Suh et al. | Jul 2008 | A1 |
20090008393 | Howlett et al. | Jan 2009 | A1 |
20090028750 | Ryan | Jan 2009 | A1 |
20090028756 | Shahriari | Jan 2009 | A1 |
20090062766 | Howlett et al. | Mar 2009 | A1 |
20090149818 | Timm | Jun 2009 | A1 |
20090149819 | Chelak | Jun 2009 | A1 |
20090175759 | Davis et al. | Jul 2009 | A1 |
20100000040 | Shaw et al. | Jan 2010 | A1 |
20100047123 | Solomon et al. | Feb 2010 | A1 |
20100049170 | Solomon et al. | Feb 2010 | A1 |
20100050351 | Colantonio et al. | Mar 2010 | A1 |
20100172794 | Ferlic et al. | Jul 2010 | A1 |
20100204648 | Stout et al. | Aug 2010 | A1 |
20100292673 | Korogi et al. | Nov 2010 | A1 |
20110150958 | Davis et al. | Jun 2011 | A1 |
20110290799 | Anderson et al. | Dec 2011 | A1 |
20120016318 | Hoang et al. | Jan 2012 | A1 |
20120039765 | Solomon et al. | Feb 2012 | A1 |
20120216360 | Rogers et al. | Aug 2012 | A1 |
20120283693 | Anderson et al. | Nov 2012 | A1 |
Number | Date | Country |
---|---|---|
1 649 890 | Apr 2006 | EP |
2 606 930 | Jun 2013 | EP |
2001-258713 | Sep 2001 | JP |
WO 8700441 | Jan 1987 | WO |
WO 9929173 | Jun 1999 | WO |
WO 2006019782 | Feb 2006 | WO |
2007044760 | Apr 2007 | WO |
2007137056 | Nov 2007 | WO |
WO 2008157092 | Dec 2008 | WO |
WO 2010039171 | Apr 2010 | WO |
2010143693 | Dec 2010 | WO |
2011053924 | May 2011 | WO |
2011066586 | Jun 2011 | WO |
Entry |
---|
“Corrected Petition for Inter Partes Review Under 35 U.S.C. §§ 311-319 and 37 C.F.R. § 42,100 et seq.,” USPTO, Patent Trial and Appeal Board, Excelsior Medical Corporation v. Becton, Dickinson and Company, Case IPR2014-00880, U.S. Pat. No. 8,740,864, pp. 1-48, Jun. 23, 2014. |
“Patent Owner's Preliminary Response Under 37 C.F.R. § 42,10,” USPTO, Patent Trial and Appeal Board, Excelsior Vledical Corporation v. Becton, Dickinson and Company, Case IPR2014-00880, U.S. Pat. No. 8,740,864, pp. 1-30, Sep. 16, 2014. |
“Decision, Institution of Inter Partes Review, 37 C.F.R. § 42,108,” USPTO, Patent Trial and Appeal Board, Excelsior Vledical Corporation v. Becton, Dickinson and Company, Case IPR2014-00880, U.S. Pat. No. 8,740,864, pp. 1-21, Nov. 25, 2014. |
Number | Date | Country | |
---|---|---|---|
20120016318 A1 | Jan 2012 | US |
Number | Date | Country | |
---|---|---|---|
61364447 | Jul 2010 | US |